{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:46:21Z","timestamp":1791924381763,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016244","name":"Stichting Health Foundation Limburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016244","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["14055"],"award-info":[{"award-number":["14055"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["REFINE-trial"],"award-info":[{"award-number":["REFINE-trial"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["project 14055"],"award-info":[{"award-number":["project 14055"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clbc.2026.09.007","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:46:42Z","timestamp":1789688802000},"page":"17-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Value of Breast and Axillary Tumor-Infiltrating Lymphocytes for Response to Neoadjuvant Chemo-(Immuno)Therapy in Clinically Node-Positive Breast Cancer"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9687-4375","authenticated-orcid":false,"given":"Melissa","family":"Lenaerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-8665","authenticated-orcid":false,"given":"Loes F.S.","family":"Kooreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florien J.G.","family":"van Amstel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-2745","authenticated-orcid":false,"given":"Paul J.","family":"van Diest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2796-729X","authenticated-orcid":false,"given":"Sander M.J.","family":"van Kuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest J.T.","family":"Luiten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4303-9776","authenticated-orcid":false,"given":"Carmen C.","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linetta B.","family":"Koppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine M.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein L.","family":"Smidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"de Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.G.","family":"Boerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.J.","family":"Brouwers-Kuyper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.E.","family":"Contant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.W.F.","family":"du M\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"Heijmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ho-Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Hulsebosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.L.R.","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Kelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.A.L.","family":"Klem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.I.","family":"Lobbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.E. Menke-","family":"Pluijmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"de Mony\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.H.M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"van Haaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"van Klaveren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Veltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.J.","family":"Vles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-3538","authenticated-orcid":false,"given":"Thiemo J.A.","family":"van Nijnatten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2026.09.007_bib0001","doi-asserted-by":"crossref","first-page":"39","DOI":"10.21037\/abs-21-109","article-title":"The neoadjuvant systemic treatment of early breast cancer: a narrative review","volume":"7","author":"Globus","year":"2023","journal-title":"Ann Breast Surg"},{"key":"10.1016\/j.clbc.2026.09.007_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.0891","article-title":"Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis","volume":"156","author":"Samiei","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.clbc.2026.09.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e43069","article-title":"Pathologic complete response and breast cancer survival post-neoadjuvant chemotherapy: a systematic review and meta-analysis of real-world data","volume":"11","author":"Antonini","year":"2025","journal-title":"Heliyon"},{"key":"10.1016\/j.clbc.2026.09.007_bib0004","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/SLA.0000000000003126","article-title":"Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy","volume":"271","author":"Samiei","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.clbc.2026.09.007_bib0005","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10549-020-05589-3","article-title":"De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study","volume":"180","author":"Simons","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.09.007_bib0006","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","article-title":"Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery","volume":"152","author":"Tadros","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.clbc.2026.09.007_bib0007","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.09.007_bib0008","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.3390\/ijms24032969","article-title":"Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review","volume":"24","author":"van den Ende","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clbc.2026.09.007_bib0009","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-021-06287-4","article-title":"Seeing the forest and the tree: tILs and PD-L1 as immune biomarkers","volume":"189","author":"Savas","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.09.007_bib0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000504055","article-title":"The immune microenvironment in breast carcinoma: predictive and prognostic role in the neoadjuvant setting","volume":"87","author":"Badr","year":"2020","journal-title":"Pathobiology"},{"key":"10.1016\/j.clbc.2026.09.007_bib0011","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.3390\/cancers14246034","article-title":"Tumor-infiltrating lymphocytes and immune response in HER2-positive breast cancer","volume":"14","author":"Luque","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2026.09.007_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12040763","article-title":"Tumor-infiltrating lymphocytes (TILs) in breast cancer: prognostic and predictive significance across molecular subtypes","volume":"12","author":"Ciarka","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.clbc.2026.09.007_bib0013","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.09.007_bib0014","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/jso.26252","article-title":"Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis","volume":"123","author":"Li","year":"2021","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.clbc.2026.09.007_bib0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10549-024-07334-6","article-title":"Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study","volume":"207","author":"Chin","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.09.007_bib0016","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10549-020-06015-4","article-title":"Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy","volume":"185","author":"Liu","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.09.007_bib0017","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00595-020-02157-6","article-title":"Predictive value of tumor-infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in breast cancer patients with axillary lymph node metastasis","volume":"51","author":"Yokotani","year":"2021","journal-title":"Surg Today"},{"key":"10.1016\/j.clbc.2026.09.007_bib0018","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.clbc.2026.09.007_bib0019","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41523-021-00292-y","article-title":"Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication","volume":"7","author":"Liu","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2026.09.007_bib0020","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/bjc.2016.92","article-title":"The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival","volume":"114","author":"Kilvaer","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2026.09.007_bib0021","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.clbc.2017.04.006","volume":"17","author":"van Nijnatten","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2026.09.007_bib0022","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/jamasurg.2022.3907","article-title":"Diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer","volume":"157","author":"Simons","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.clbc.2026.09.007_bib0023","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znae203","article-title":"Disease extent according to baseline [18F]fluorodeoxyglucose PET\/CT and molecular subtype: prediction of axillary treatment response after neoadjuvant systemic therapy for breast cancer","volume":"111","author":"van Amstel","year":"2024","journal-title":"Br J Surg"},{"key":"10.1016\/j.clbc.2026.09.007_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2019.108773","article-title":"Correlation between (18)F-FDG uptake on PET\/MRI and the level of tumor-infiltrating lymphocytes (TILs) in triple-negative and HER2-positive breast cancer","volume":"123","author":"Murakami","year":"2020","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.clbc.2026.09.007_bib0025","article-title":"Evaluating the correlation between pretreatment (18)F-FDG PET\/CT metabolic parameters and tumor-infiltrating lymphocyte levels in nonluminal breast cancer and impact on survival","volume":"30","author":"Tamam","year":"2024","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.clbc.2026.09.007_bib0026","first-page":"2647","article-title":"Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis","volume":"17","author":"Kurozumi","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clbc.2026.09.007_bib0027","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tjem.2018.08.001","article-title":"User's guide to correlation coefficients","volume":"18","author":"Akoglu","year":"2018","journal-title":"Turk J Emerg Med"},{"key":"10.1016\/j.clbc.2026.09.007_bib0028","first-page":"614","article-title":"Biostatistics 104: correlational analysis","volume":"44","author":"Chan","year":"2003","journal-title":"Singapore Med J"},{"key":"10.1016\/j.clbc.2026.09.007_bib0029","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","article-title":"Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: neoPACT phase 2 clinical trial","volume":"10","author":"Sharma","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2026.09.007_bib0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.breast.2022.10.001","article-title":"Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: a meta-analysis","volume":"66","author":"Li","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2026.09.007_bib0031","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.ajpath.2021.05.006","article-title":"The multifaceted effects of breast cancer on tumor-draining lymph nodes","volume":"191","author":"Jana","year":"2021","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clbc.2026.09.007_bib0032","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-017-2061-4","article-title":"Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease","volume":"67","author":"Diem","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clbc.2026.09.007_bib0033","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10549-018-4842-7","article-title":"Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis","volume":"171","author":"Cha","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.09.007_bib0034","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/modpathol.2017.43","article-title":"Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer","volume":"30","author":"Buisseret","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2026.09.007_bib0035","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1093\/annonc\/mdx309","article-title":"Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer","volume":"28","author":"Hamy","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.09.007_bib0036","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/annonc\/mdy547","article-title":"Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy","volume":"30","author":"Luen","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.09.007_bib0037","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.21873\/anticanres.14142","article-title":"Changes in tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and clinical significance in triple negative breast cancer","volume":"40","author":"Lee","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clbc.2026.09.007_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1436581","article-title":"Immune-mediated inflammatory diseases and cancer - a dangerous liaison","volume":"15","author":"Maier","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.clbc.2026.09.007_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.979116","article-title":"Tumor accomplice: t cell exhaustion induced by chronic inflammation","volume":"13","author":"Fang","year":"2022","journal-title":"Front Immunol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:00:34Z","timestamp":1791921634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926001709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1526820926001709"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.09.007","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Value of Breast and Axillary Tumor-Infiltrating Lymphocytes for Response to Neoadjuvant Chemo-(Immuno)Therapy in Clinically Node-Positive Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}